Allena Pharmaceuticals, Inc. Depreciation & Amortization

Depreciation & Amortization of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending March 31, 2022 was $125 Thousand (a -41.31% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization decreased by -33.16%
  • Annual Depreciation & Amortization for 2021 was $735 Thousand (a -4.17% decrease from previous year)
  • Annual Depreciation & Amortization for 2020 was $767 Thousand (a 370.55% increase from previous year)
  • Annual Depreciation & Amortization for 2019 was $163 Thousand (a 108.97% increase from previous year)
  • Twelve month Depreciation & Amortization ending March 31, 2022 was $712 Thousand (a -3.13% decrease compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization increased by 15.21% year-over-year
Trailing Depreciation & Amortization for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$712 Thousand $735 Thousand $765 Thousand $618 Thousand
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of Allena Pharmaceuticals, Inc.

Most recent Depreciation & Amortizationof ALNA including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.13
2021 $0.21 $0.19 $0.19 $0.15 $0.74
2020 $0.24 $0.04 $0.04 $0.04 $0.77
2019 $0.04 $0.04 $0.04 $0.04 $0.16
2018 $0.03 $0.02 $0.01 $0.02 $0.08
2017 $0.02 $0.02 $0.02 $0.05 $0.07
2016 $0.06 $0.13 $0.2
2015 $0.09 $0.1

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.